INITIAL TREATMENT RESULTS USING CYBERKNIFE FOR HEAD AND NECK TUMOR
|
Accession number;04A0146758
|
| Title;INITIAL TREATMENT RESULTS USING CYBERKNIFE FOR HEAD AND NECK TUMOR |
| Author;
HIMEI KENGO
(Okayama Medical Univ., Hospital, JPN)
KATSUI KUNIAKI
(Okayama Medical Univ., Hospital, JPN)
YOSHIDA ATSUSHI
(Okayama Medical Univ., Hospital, JPN)
TAKEMOTO MITSUHIRO
(Okayama Medical Univ., Hospital, JPN)
KOBAYASHI MITSURU
(Okayama Medical Univ., Hospital, JPN)
KURODA MASAHIRO
(Okayama Medical Univ., Hospital, JPN)
SATO KENGO
(Okayamakyokutobyoin Noshinkeigeka)
BABA YOSHIMI
(Okayamakyokutobyoin Noshinkeigeka)
HIRAKI YOSHIO
(Okayama Medical Univ., Hospital, JPN)
|
Journal Title;Head and Neck Cancer
|
Journal Code:Y0503A
|
ISSN:0911-4335
|
|
VOL.28;NO.1;PAGE.186-191(2002)
|
| Figure&Table&Reference;FIG.2, TBL.1, REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The CyberKnife, a medical device for stereotactic radiotherapy, is composed of a combination of a robot manipulator and LINAC. For the treatment of head and neck tumors, this system has been applied. Between June 2000 and January 2001, 18 patients with head and neck tumor were treated with this system because of tumor recurrence, difficulty in surgery or additional increase after external radiotherapy. The median age was 64 years. Primary lesions were skull base (4), nasopharynx (3), paranasal sinus (3), nasal cavity (2), lacrimal gland (1), oropharynx (1), oral floor (1), and buccul mucosa (1), metastatic Lymph nodes were found in three. The prescribed dose was 12-38Gy as for marginal dose. The response rate (CR+PR) was 44.4% and local control rate (CR+PR+NC) was 77.8%. The adverse effects were assessed by the NCI-CTC Version 2.0 and observed grade 3 in two cases. Our early experience indicates that this system could to be feasible for the treatment of locally advanced or recurrent head and neck tumor, and for the reduction of adverse effect and maintenance of useful QOL of patients. (author abst.) |
|
|
|
Related Articles;
|
|
